Business Wire

SOSAFE

24.5.2024 10:41:26 CEST | Business Wire | Press release

Share
SoSafe Introduces The Human Risk OS™, Leading the Category Evolution Towards Human Risk Management

SoSafe, Europe’s largest security awareness and human risk management vendor, has announced the launch of their pioneering Human Risk Operating System, The Human Risk OS™, a set of capabilities designed to help customers identify, quantify, monitor, and intervene on human security risk. SoSafe has also presented new capabilities to its Sofie Human Security Copilot, an AI-powered multi-channel agent built entirely on advanced Large Language Models, as well as incremental updates to its flagship product offering such as next-level personalized learning, behavioral phishing simulation, novel security operations and 3rd party data integrations. With that, SoSafe is leading the category evolution from security awareness to human risk management in response to escalating cyber threats and the need for security strategies to address human risk more holistically.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524947770/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoSafe launches The Human Risk OS™, bringing together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. Copyright: SoSafe GmbH

Dr Niklas Hellemann, Psychologist and CEO at SoSafe: “To achieve real risk reduction and meet the demands of security leaders, basic awareness measures alone don’t cut it. While traditional and generic awareness programs focus on awareness and knowledge transfer–educating individuals about potential threats and instructing them on response strategies–this approach often falls short in today’s dynamic environment. The evolving landscape requires an evolution to holistic human risk management, which prioritizes the outcomes and the drivers of behavior and helps to sustainably mitigate human risks.”

The Human Risk OS brings together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. It focuses on proactively managing security risks through real-time risk detection and continuous analyses, provides enhanced behavioural insights and recommends targeted interventions to customize and optimize defensive responses.

Its three core elements are:

  • Human Behavior Sensors measure an organization’s digital activities, behaviors, and security culture, creating individual and group-level profiles of security behavior.
  • The Human Security Index processes this tracked data and additional contextual information such as level of seniority, tenure, digital access, and functional criticality to create a single index that summarizes security performance for groups and organizations. This score allows organizations to quickly identify concern areas, track progress, and evolution over time, and the impact of different possible interventions.
  • The Intervention Hub suggests intervention strategies to mitigate human-related security risks and drive behavioral change and healthy security.

Gonçalo Gaiolas, CPO at SoSafe: “We believe in the power of people in the fight against cybercrime. With The Human Risk OS™, organizations invest in more than just a security solution—they invest in a proactive approach to mitigating human-centric risk and securing their organization's future by putting people at the very center of their efforts. We empower organizations to drive behavioral change and build security cultures by identifying, quantifying, actively managing, and reducing their human risk and by focusing on efficiency to relieve the pressure on overstretched security teams.”

SoSafe also introduced additional capabilities to its “Sofie Human Security Copilot”, an AI-powered multi-channel agent built to meaningfully reduce human risk. Sofie supports security professionals and users with rapid threat awareness, situational awareness, and zero-level security and compliance support. Security leaders can now incorporate organisational policies and specifics into their responses. Built on advanced large language models and featuring an engaging interface, Sofie provides answers to support questions at any time, sends urgent security alerts, and educates users on security best practices, all customized to specific organizational needs and policies.

Unlike other conversational AI-solutions, Sofie focuses on making each interaction with the end user a learning moment in their daily work environment, not just delivering informative content, but also aiming to change behavior.

Gonçalo Gaiolas: “Cybercriminals are already harnessing the power of AI to enhance their social engineering attacks. It's time to use the full potential of AI on the defensive side as well. Our AI-powered multi-channel agent ‘Sofie’ demonstrates the power of AI for cyber defenses: It’s a multifunctional tool that makes security information accessible to everyone anytime, provides learning opportunities in every interaction, and supports security administrators with content and communication, automating responses to free up their team’s capacity. ‘Sofie’ makes cybersecurity part of our everyday work, manifesting security cultures as the most essential part of holistic human risk management.”

Ilona Simpson, longstanding CIO and Executive Advisor at SoSafe: “SoSafe’s Human Risk OS™ and Sofie help security leaders to efficiently drive a human risk management strategy that sustainably mitigates risk. Based on behavioral data and fueled with new technology, SoSafe simplifies where others complicate, making it easy for security professionals to strengthen the human layer as the most versatile part of our defense strategy. SoSafe's focus on automation and efficiency not only saves security teams significant time but also amplifies their results, enhancing overall security posture.”

SoSafe presented its product innovations “The Human Risk OS™” and “Sofie Human Security Copilot” with its new capabilities during a launch event on May 23rd in Cologne, Germany and via livestream in front of more than 300 industry guests.

About SoSafe

SoSafe, founded by a team of behavioral scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioral science, SoSafe enhances secure behavior across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defense by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.

Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240524947770/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye